/OPNT
OPNT Stock - Opiant Pharmaceuticals, Inc.
Healthcare|BiotechnologyNASDAQ
$20.65+0.00%
+$0.00 (+0.00%) • Mar 1
72
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.81
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.87
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $22.71
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for OPNT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$20.44 – $20.86
TARGET (TP)$23.75
STOP LOSS$19.00
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.83
52W High$27.36
52W Low$7.34
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|
| Revenue | $40.73M | $27.40M | $38.24M | $13.51M | $18.45M |
| Gross Profit | $31.66M | $21.20M | $30.52M | $12.02M | $18.45M |
| Gross Margin | 77.7% | 77.4% | 79.8% | 89.0% | 100.0% |
| Operating Income | $5.16M | $-2,241,000 | $10.91M | $-21,190,000 | $7.09M |
| Net Income | $3.01M | $-1,861,000 | $11.59M | $-21,195,000 | $6.58M |
| Net Margin | 7.4% | -6.8% | 30.3% | -156.8% | 35.7% |
| EPS | $0.68 | $-0.44 | $2.88 | $-7.10 | $3.27 |
Company Overview
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Santa Monica, California.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
OPNTBeat Rate
68%
Last 19 quarters
Avg Surprise
+195.8%
EPS vs Estimate
Beats / Misses
13/6
Last 12 quarters
Latest EPS
$0.11
Q1 2023
EPS Surprise History
Q2 21
+7.0%
$-0.66vs$-0.71
Q3 21
+210.7%
$0.31vs$-0.28
Q4 21
+166.7%
$0.56vs$0.21
Q1 22
+1200.2%
$0.11vs$0.01
Q2 22
-167.0%
$-2.43vs$-0.91
Q3 22
-69.9%
$-2.31vs$-1.36
Q4 22
-28.9%
$-1.92vs$-1.49
Q1 23
+104.5%
$0.11vs$-2.46
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2023 | Mar 21, 2023 | $-2.46 | $0.11 | +104.5% | ✓ BEAT |
Q4 2022 | Nov 14, 2022 | $-1.49 | $-1.92 | -28.9% | ✗ MISS |
Q3 2022 | Aug 11, 2022 | $-1.36 | $-2.31 | -69.9% | ✗ MISS |
Q2 2022 | May 10, 2022 | $-0.91 | $-2.43 | -167.0% | ✗ MISS |
Q1 2022 | Mar 15, 2022 | $0.01 | $0.11 | +1200.2% | ✓ BEAT |
Q4 2021 | Nov 11, 2021 | $0.21 | $0.56 | +166.7% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $-0.28 | $0.31 | +210.7% | ✓ BEAT |
Q2 2021 | May 11, 2021 | $-0.71 | $-0.66 | +7.0% | ✓ BEAT |
Q1 2021 | Mar 4, 2021 | $0.07 | $-0.16 | -328.6% | ✗ MISS |
Q4 2020 | Nov 12, 2020 | $-0.21 | $0.15 | +171.4% | ✓ BEAT |
Q3 2020 | Aug 6, 2020 | $-0.24 | $-0.05 | +79.2% | ✓ BEAT |
Q2 2020 | May 12, 2020 | $-0.19 | $-0.40 | -110.5% | ✗ MISS |
Q1 2020 | Mar 4, 2020 | $-2.13 | $0.20 | +109.4% | ✓ BEAT |
Q4 2019 | Nov 12, 2019 | $-0.09 | $1.97 | +2288.9% | ✓ BEAT |
Q3 2019 | Aug 8, 2019 | $-0.55 | $0.31 | +156.4% | ✓ BEAT |
Q2 2019 | May 9, 2019 | $-0.79 | $-0.44 | +44.3% | ✓ BEAT |
Q1 2019 | Mar 21, 2019 | $-0.13 | $-0.37 | -184.6% | ✗ MISS |
Q4 2018 | Nov 7, 2018 | $-0.40 | $-0.32 | +20.0% | ✓ BEAT |
Q3 2018 | Aug 9, 2018 | $-1.07 | $-0.52 | +51.4% | ✓ BEAT |
Q2 2018 | May 8, 2018 | — | $-3.68 | — | — |
Latest News
Loading news...
Frequently Asked Questions about OPNT
What is OPNT's current stock price?
Opiant Pharmaceuticals, Inc. (OPNT) is currently trading at $20.65 per share. The stock has moved +0.00% today.
What is the analyst price target for OPNT?
No analyst price targets are currently available for this stock.
What sector is Opiant Pharmaceuticals, Inc. in?
Opiant Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is OPNT's market cap?
Opiant Pharmaceuticals, Inc. has a market capitalization of $0.11 billion, making it a small-cap company.
Does OPNT pay dividends?
No, Opiant Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAADI
Aadi Bioscience, Inc.
$2.05
Mkt Cap: $0.1B
CYT
Cyteir Therapeutics, Inc.
$3.02
Mkt Cap: $0.1B
DBTX
Decibel Therapeutics, Inc.
$4.91
Mkt Cap: $0.1B
GRAY
Graybug Vision, Inc.
$5.50
Mkt Cap: $0.1B
HLVX
HilleVax, Inc.
$2.09
Mkt Cap: $0.1B
JNCE
Jounce Therapeutics, Inc.
$1.88
Mkt Cap: $0.1B
MIRO
Miromatrix Medical Inc.
$3.39
Mkt Cap: $0.1B
PRTK
Paratek Pharmaceuticals, Inc.
$2.23
Mkt Cap: $0.1B
RVLP
RVL Pharmaceuticals plc
$0.03
Mkt Cap: $0.0B
TRML
Tourmaline Bio, Inc.
$47.98
Mkt Cap: $1.2B
Explore stocks similar to OPNT for comparison